代谢组学在慢性肾脏病生物标志物临床研究中的应用  

Application of metabolomics in clinical research on chronic kidney disease biomarkers

作　　者：许倬 李娇[1] 张利[1] 陈香美[1] Xu Zhuo;Li Jiao;Zhang Li;Chen Xiangmei(Department of Nephrology,Chinese PLA General Hospital,Chinese PLA Institute of Nephrology,State Key Laboratory of Kidney Diseases,National Clinical Research Center for Kidney Diseases,Beijing 100853;Department of Nephrology,General Hospital of Chinese PLA Rocket Force,Beijing 100088,China)

机构地区：[1]解放军总医院肾脏病科解放军肾脏病研究所肾脏疾病国家重点实验室国家慢性肾病临床医学研究中心,北京100853 [2]火箭军总医院肾脏病科,北京100088

出　　处：《中华肾病研究电子杂志》2018年第5期224-225,228-230,共3页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：国家重点基础研究发展计划资助课题(2015CB553605)

摘　　要：代谢组学是对小分子代谢物进行鉴定和定量分析的新型组学,它反映了生物体内实时的病理生理状态。肾脏是重要的代谢器官,肾脏疾病对循环代谢物水平可产生广泛影响。近年来代谢组学越来越多地用于慢性肾脏病的研究,以发现能够早期诊断、预测疾病进展的生物标志物,并探索其发病机制。Metabolomics is a new type of omics for identifying and quantifying the small molecule metabolites,and reflects the real-time pathophysiological conditions in the living organisms.Renal disorders have a wide-ranging influences on circulating metabolites since the kidney is a vital organ for metabolite handling.In recent years,metabolomics has increasingly been used in chronic kidney disease research to discover new biomarkers for early diagnosis or prediction of progression,and to explore the kidney disease pathogenesis.

关 键 词：代谢组学 慢性肾脏病 生物标志物 

分 类 号：R692[医药卫生—泌尿科学]